TY  -  
T1  - Efficacy and safety of treatment with dupilumab for severe asthma : A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma 
SN  -  /  
UR  - http://hdl.handle.net/10138/326686 
T3  -  
A1  - Agache, Ioana; Song, Yang; Rocha, Claudio; Beltran, Jessica; Posso, Margarita; Steiner, Corinna; Alonso-Coello, Pablo; Akdis, Cezmi; Akdis, Mubeccel; Canonica, Giorgio Walter; Casale, Thomas; Chivato, Tomas; Corren, Jonathan; del Giacco, Stefano; Eiwegger, Thomas; Firinu, Davide; Gern, James E.; Hamelmann, Eckard; Hanania, Nicola; Mäkelä, Mika; Martin, Irene Hernandez; Nair, Parameswaran; O'Mahony, Liam; Papadopoulos, Nikolaos G.; Papi, Alberto; Park, Hae-Sim; de Llano, Luis Perez; Quirce, Santiago; Sastre, Joaquin; Shamji, Mohamed; Schwarze, Jurgen; Canelo-Aybar, Carlos; Palomares, Oscar; Jutel, Marek 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review evaluated the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important asthma-related outcomes were evaluated. The risk of bias and... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - cost-effectiveness; dupilumab; exacerbations; oral corticosteroids; severe asthma; WILLINGNESS-TO-PAY; ECONOMIC EVALUATIONS; QUALITY; BURDEN; INFORMATION; SURROGATES; EURONHEED; CONSENSUS; GRADE; FENO; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -